Trial Profile
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Vorinostat (Primary)
- Indications CNS cancer; Lymphoma; Solid tumours
- Focus Adverse reactions
- 23 Feb 2017 New trial record